EXEL
EXELIXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$62.68
+0.72%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$61.84
From 52W high−0.24%
Volume1.93M
Market cap$15.53B
P/E (TTM)19.1x
P/S (TTM)6.4x
Div yield—
Key dataOct 19, 2026
Open
$61.84
From 52W high
−0.24%
Volume
1.93M
Market cap
$15.53B
ValuationView details →
P/E (Fwd)
16.4x
EV/EBITDA
14.2x
P/E (TTM)
19.1x
RSI (14)
68.6
MomentumView details →
1D Return
+0.72%
YTD Return
+42.44%
SummaryUpdated Jul 1, 2026
Exelixis, Inc. (NASDAQ:EXEL) is an oncology-focused biotechnology company founded in 1994 and headquartered in Alameda, California. Originally incorporated as Exelixis Pharmaceuticals, Inc., the company changed its name to Exelixis, Inc. in February 2000 and went public that same year. What began as a drug discovery company has evolved into a leading commercial-stage biotechnology firm specializing in cancer treatments. Today, Exelixis has successfully transitioned from a research-focused organization to a profitable company with multiple approved cancer therapies and a robust pipeline of experimental treatments targeting various solid tumors.
Similar companies
Latest newsMore news →
Kuehn Law, PLLC announced an investigation into whether certain EXELIXIS, INC. officers and directors breached fiduciary duties to shareholders through potential self-dealing.7d agoThe FDA approved Merck & Co.'s Welireg (belzutifan) in combination with Eisai's Lenvima (lenvatinib) for advanced clear-cell renal cell carcinoma following treatment with a PD-(L)1 inhibitor.25d ago